Pfizer (PFE) Total Current Liabilities (2016 - 2025)
Pfizer (PFE) has disclosed Total Current Liabilities for 16 consecutive years, with $43.0 billion as the latest value for Q4 2024.
- On a quarterly basis, Total Current Liabilities fell 10.04% to $43.0 billion in Q4 2024 year-over-year; TTM through Dec 2024 was $43.0 billion, a 10.04% decrease, with the full-year FY2024 number at $43.0 billion, down 10.04% from a year prior.
- Total Current Liabilities was $43.0 billion for Q4 2024 at Pfizer, roughly flat from $43.2 billion in the prior quarter.
- In the past five years, Total Current Liabilities ranged from a high of $47.8 billion in Q4 2023 to a low of $5.1 billion in Q4 2021.
- A 5-year average of $33.1 billion and a median of $36.1 billion in 2021 define the central range for Total Current Liabilities.
- Peak YoY movement for Total Current Liabilities: plummeted 30.52% in 2020, then surged 763.32% in 2022.
- Pfizer's Total Current Liabilities stood at $25.9 billion in 2020, then surged by 64.63% to $42.7 billion in 2021, then fell by 1.25% to $42.1 billion in 2022, then increased by 13.42% to $47.8 billion in 2023, then dropped by 10.04% to $43.0 billion in 2024.
- Per Business Quant, the three most recent readings for PFE's Total Current Liabilities are $43.0 billion (Q4 2024), $43.2 billion (Q3 2024), and $47.8 billion (Q4 2023).